- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, chief of the Division of Hematology at Sylvester Comprehensive Cancer Center, University of Miami, and chair of the American Society of Hematology (ASH) Committee on Communications
Articles
Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS
February 7th 2025Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) conditioning in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Treosulfan Shown Effective, Safe as Conditioning for Allo-HSCT in AML/MDS
February 6th 2025Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, discussed data supporting the FDA approval of treosulfan as part of conditioning for allogeneic hematopoeitic stem cell transplantation (allo-HSCT).
